Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Oral minoxidil is gaining popularity due to increased awareness and convenience, despite potential side effects like cardiac issues and unwanted hair growth. Users report mixed results, with some seeing significant regrowth and others experiencing side effects or minimal improvement.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.

Minoxidil is typically applied once daily, with some users opting for foam to minimize irritation. Users often combine it with finasteride or use oral minoxidil for improved results, while managing scalp irritation with ketoconazole or salicylic acid shampoos.

Trump's health report omits finasteride, sparking speculation about whether he stopped using it or switched treatments. Some believe he might not prioritize hair maintenance anymore.

Finasteride and dutasteride are significantly cheaper in India, leading to substantial savings for users. There are discussions on the effectiveness of oral minoxidil and finasteride for hair loss, with concerns about the quality of generic medications.

Excessive sugar consumption may contribute to male pattern hair loss by increasing androgen sensitivity and insulin resistance, but genetics play a significant role. Treatments like minoxidil and finasteride are suggested for managing hair loss, while reducing sugar intake and maintaining a healthy lifestyle may help mitigate its progression.

An 18-year-old started taking 1mg of finasteride daily to address receding temples and is concerned about whether they will need to increase the dose or switch to dutasteride in the future. Users discuss that finasteride can slow hair loss for many years, but it is not a permanent solution, and individual responses vary.

Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user is frustrated with hair regrowth despite using finasteride, minoxidil, dutasteride, RU58841, ketoconazole shampoo, and dermastamping. Others suggest improvement, advise against overmedication, and recommend consulting a doctor or considering a simpler regimen or hair transplant.

Finasteride is used to stop hair loss, with results taking 6-12 months. Adding minoxidil can help regrow hair, but both require patience.

Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.

A user reported significant hair improvement after one month of using dutasteride and oral minoxidil. Others expressed skepticism, attributing perceived changes to lighting and styling, and debated the effectiveness and risks of these treatments.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

The conversation is about overcoming fear of finasteride/dutasteride for hair loss treatment. Users suggest starting with a small supply, noting side effects are rare and reversible, and emphasize personal comfort and confidence.

Hair loss deeply affects self-esteem and mental health. Treatments mentioned include hair transplants, Minoxidil, Finasteride, and RU58841.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

A user shared a 9-month hair recovery journey from androgenic alopecia using 1 mg finasteride daily, 5% minoxidil twice daily, and weekly dermarolling with a 1.5 mm roller. Some responders were skeptical about the authenticity of the results, while others confirmed the consistency of the user's appearance and supported the effectiveness of the treatment.

The user successfully treated their hair loss using 1ml of minoxidil twice daily and dermarolling with a 1.5mm dermaroller once a week. They experienced noticeable results only after combining minoxidil with dermarolling, and they have not used finasteride.

A user shared their frustration about their cousin's refusal to take their advice on using finasteride for aggressive hair loss, despite the cousin's desperation and current use of minoxidil and consideration of PRP injections. The user, who has done extensive research, suggested the cousin needs a 5ar inhibitor, but the cousin dismisses the advice because the user isn't a doctor.

The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hair follicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.